EntryPoint Capital LLC Has $354,000 Position in CareDx, Inc (NASDAQ:CDNA)

EntryPoint Capital LLC boosted its holdings in CareDx, Inc (NASDAQ:CDNA) by 33.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,522 shares of the company’s stock after acquiring an additional 4,182 shares during the quarter. EntryPoint Capital LLC’s holdings in CareDx were worth $354,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Quarry LP bought a new stake in shares of CareDx in the 3rd quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd bought a new stake in CareDx in the third quarter valued at $52,000. Plato Investment Management Ltd raised its stake in CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock worth $116,000 after acquiring an additional 1,370 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of CareDx by 37.8% during the third quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock valued at $175,000 after acquiring an additional 1,540 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of CareDx in the 4th quarter valued at $208,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CDNA shares. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Stephens restated an “overweight” rating and set a $40.00 price target on shares of CareDx in a research report on Thursday, February 27th. Finally, HC Wainwright cut their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, CareDx has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Price Performance

Shares of CareDx stock opened at $18.23 on Thursday. The firm has a 50 day simple moving average of $21.54 and a 200 day simple moving average of $23.78. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The firm has a market cap of $1.01 billion, a P/E ratio of -6.75 and a beta of 1.95.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. The firm had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. On average, sell-side analysts expect that CareDx, Inc will post -0.9 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.